Abstract
Summary
The global market for Nucleic Acid-based Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid-based Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Nucleic Acid-based Drugs by region & country, by Type, and by Application.
The Nucleic Acid-based Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid-based Drugs.
Market Segmentation
By Company
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
Segment by Type:
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Nucleic Acid-based Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Nucleic Acid-based Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Nucleic Acid-based Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid-based Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Nucleic Acid-based Drugs by region & country, by Type, and by Application.
The Nucleic Acid-based Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid-based Drugs.
Market Segmentation
By Company
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
Segment by Type:
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Nucleic Acid-based Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Nucleic Acid-based Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Nucleic Acid-based Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Nucleic Acid-based Drugs Product Introduction
1.2 Global Nucleic Acid-based Drugs Market Size Forecast
1.3 Nucleic Acid-based Drugs Market Trends & Drivers
1.3.1 Nucleic Acid-based Drugs Industry Trends
1.3.2 Nucleic Acid-based Drugs Market Drivers & Opportunity
1.3.3 Nucleic Acid-based Drugs Market Challenges
1.3.4 Nucleic Acid-based Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Nucleic Acid-based Drugs Players Revenue Ranking (2023)
2.2 Global Nucleic Acid-based Drugs Revenue by Company (2019-2024)
2.3 Key Companies Nucleic Acid-based Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Nucleic Acid-based Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Nucleic Acid-based Drugs
2.6 Nucleic Acid-based Drugs Market Competitive Analysis
2.6.1 Nucleic Acid-based Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Nucleic Acid-based Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid-based Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 ASO
3.1.2 mRNA
3.1.3 siRNA
3.1.4 miRNA
3.1.5 saRNA
3.1.6 Aptamer
3.2 Global Nucleic Acid-based Drugs Sales Value by Type
3.2.1 Global Nucleic Acid-based Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Nucleic Acid-based Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Nucleic Acid-based Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Genetic Disease
4.1.2 Cancer
4.1.3 Cardiovascular Diseases
4.1.4 Other
4.2 Global Nucleic Acid-based Drugs Sales Value by Application
4.2.1 Global Nucleic Acid-based Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Nucleic Acid-based Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Nucleic Acid-based Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Nucleic Acid-based Drugs Sales Value by Region
5.1.1 Global Nucleic Acid-based Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Nucleic Acid-based Drugs Sales Value by Region (2019-2024)
5.1.3 Global Nucleic Acid-based Drugs Sales Value by Region (2025-2030)
5.1.4 Global Nucleic Acid-based Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Nucleic Acid-based Drugs Sales Value, 2019-2030
5.2.2 North America Nucleic Acid-based Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Nucleic Acid-based Drugs Sales Value, 2019-2030
5.3.2 Europe Nucleic Acid-based Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Nucleic Acid-based Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific Nucleic Acid-based Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Nucleic Acid-based Drugs Sales Value, 2019-2030
5.5.2 South America Nucleic Acid-based Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Nucleic Acid-based Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa Nucleic Acid-based Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Nucleic Acid-based Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Nucleic Acid-based Drugs Sales Value
6.3 United States
6.3.1 United States Nucleic Acid-based Drugs Sales Value, 2019-2030
6.3.2 United States Nucleic Acid-based Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Nucleic Acid-based Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Nucleic Acid-based Drugs Sales Value, 2019-2030
6.4.2 Europe Nucleic Acid-based Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Nucleic Acid-based Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Nucleic Acid-based Drugs Sales Value, 2019-2030
6.5.2 China Nucleic Acid-based Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Nucleic Acid-based Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Nucleic Acid-based Drugs Sales Value, 2019-2030
6.6.2 Japan Nucleic Acid-based Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Nucleic Acid-based Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Nucleic Acid-based Drugs Sales Value, 2019-2030
6.7.2 South Korea Nucleic Acid-based Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Nucleic Acid-based Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Nucleic Acid-based Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Nucleic Acid-based Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Nucleic Acid-based Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Nucleic Acid-based Drugs Sales Value, 2019-2030
6.9.2 India Nucleic Acid-based Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Nucleic Acid-based Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Ionis Pharmaceuticals
7.1.1 Ionis Pharmaceuticals Profile
7.1.2 Ionis Pharmaceuticals Main Business
7.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Products, Services and Solutions
7.1.4 Ionis Pharmaceuticals Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 Ionis Pharmaceuticals Recent Developments
7.2 Sarepta Therapeutics
7.2.1 Sarepta Therapeutics Profile
7.2.2 Sarepta Therapeutics Main Business
7.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
7.2.4 Sarepta Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Sarepta Therapeutics Recent Developments
7.3 Nippon Shinyaku
7.3.1 Nippon Shinyaku Profile
7.3.2 Nippon Shinyaku Main Business
7.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Products, Services and Solutions
7.3.4 Nippon Shinyaku Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 BioNTech Recent Developments
7.4 BioNTech
7.4.1 BioNTech Profile
7.4.2 BioNTech Main Business
7.4.3 BioNTech Nucleic Acid-based Drugs Products, Services and Solutions
7.4.4 BioNTech Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 BioNTech Recent Developments
7.5 Moderna Therapeutics
7.5.1 Moderna Therapeutics Profile
7.5.2 Moderna Therapeutics Main Business
7.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
7.5.4 Moderna Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Moderna Therapeutics Recent Developments
7.6 CureVac
7.6.1 CureVac Profile
7.6.2 CureVac Main Business
7.6.3 CureVac Nucleic Acid-based Drugs Products, Services and Solutions
7.6.4 CureVac Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 CureVac Recent Developments
7.7 Alnylam Pharmaceuticals
7.7.1 Alnylam Pharmaceuticals Profile
7.7.2 Alnylam Pharmaceuticals Main Business
7.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Products, Services and Solutions
7.7.4 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 Alnylam Pharmaceuticals Recent Developments
7.8 Regulus Therapeutics
7.8.1 Regulus Therapeutics Profile
7.8.2 Regulus Therapeutics Main Business
7.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
7.8.4 Regulus Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 Regulus Therapeutics Recent Developments
7.9 Miragen Therapeutics
7.9.1 Miragen Therapeutics Profile
7.9.2 Miragen Therapeutics Main Business
7.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
7.9.4 Miragen Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 Miragen Therapeutics Recent Developments
7.10 Mina Therapeutics
7.10.1 Mina Therapeutics Profile
7.10.2 Mina Therapeutics Main Business
7.10.3 Mina Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
7.10.4 Mina Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Mina Therapeutics Recent Developments
7.11 NeXstar Pharmaceuticals
7.11.1 NeXstar Pharmaceuticals Profile
7.11.2 NeXstar Pharmaceuticals Main Business
7.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Products, Services and Solutions
7.11.4 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 NeXstar Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Nucleic Acid-based Drugs Industrial Chain
8.2 Nucleic Acid-based Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Nucleic Acid-based Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Nucleic Acid-based Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer